Bayer's Seven-Day Surge Tied to Legal Relief Hopes as Missouri Jury Hands Monsanto a Win
Published on 11/09/2026 at 15:31 | Editorial boerse-global.de
Bayer shares have climbed 12% over the past seven days, a move Euronews links to a broader rotation in European equities following the US midterm elections — and to growing optimism that the company's legal overhang may be easing.
At the center of that optimism sits Bank of America's read on Bayer's litigation exposure. The US bank argues that diminished legal risks could clear a path toward stronger cash flow and a lighter debt load, according to a Euronews report published today.
A Jury Verdict and a Settlement Still in Limbo
The legal picture is mixed. Monsanto, Bayer's subsidiary, won a Roundup case in Missouri on 29 October, with the jury ruling unanimously in the company's favor across claims brought by three women, according to Bayer. That verdict is separate from a proposed $7.25 billion settlement, which remains under review by a Missouri court.
Bayer CEO Bill Anderson said roughly a week ago that the company expects a decision before Christmas, Reuters reported. That is the company's own expectation, not a confirmed ruling date.
Should investors sell immediately? Or is it worth buying Bayer?
Guidance Raised, With Cash Flow Still in the Red
Bayer lifted its 2026 outlook about a week ago. On a currency-adjusted basis, the group targets EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion.
Free cash flow is still projected to land in negative territory for 2026, at minus EUR 1.5 billion to minus EUR 0.5 billion. Net financial debt is expected to reach EUR 28.0 billion to EUR 29.0 billion by year-end.
Pharma Drives the Top Line as Earnings Slip
Third-quarter 2026 revenue rose to EUR 10.1 billion, while EBITDA before special items climbed to EUR 1.62 billion. The pharmaceuticals division generated EUR 4.68 billion in sales, up 6.4% on a currency- and portfolio-adjusted basis, and Bayer credits the unit with carrying the quarter's growth.
Profitability told a different story: the group posted a quarterly loss of EUR 0.7 billion, and adjusted earnings per share fell to EUR 0.31.
Bayer at a turning point? This analysis reveals what investors need to know now.
Brokers Move in Opposite Directions
Analyst reaction has been split. UBS raised its price target on Bayer to EUR 66 from EUR 62 on 3 November while keeping a "Buy" rating, according to media reports. J.P. Morgan reaffirmed "Overweight" with a EUR 61 target the same day.
Bayer also said on 3 November that it will present new data on cardiovascular disease, kidney conditions and stroke at the AHA Scientific Sessions, scheduled for 6–9 November 2026 in Chicago.
Ad
Bayer Stock: New Analysis - 9 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
